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The excess mortality in people with psychotic disorders is 
a major public health concern, but little is known about 
the clinical and social risk factors which may predict this 
health inequality and help inform preventative strategies. 
We aimed to investigate mortality in a large epidemio-
logically characterized cohort of individuals with first-
episode psychosis compared with the general population 
and to determine clinical and social risk factors for pre-
mature death. All 557 individuals with first-episode psy-
chosis initially identified in 2 areas (Southeast London 
and Nottinghamshire, United Kingdom) were traced over 
a 10-year period in the ӔSOP-10 study. Compared with 
the general population, all-cause (standardized mortality 
ratio [SMR] 3.6, 95% confidence interval [CI] 2.6–4.9), 
natural-cause (SMR 1.7, 95% CI 1.0–2.7) and unnatural-
cause (SMR 13.3, 95% CI 8.7–20.4) mortality was very 
high. Illicit drug use was associated with an increased risk 
of all-cause mortality (adj. rate ratio [RR] 2.31, 95% CI 
1.06–5.03). Risk of natural-cause mortality increased with 
a longer time to first remission (adj. RR 6.61, 95% CI 
1.33–32.77). Family involvement at first contact strongly 
reduced risk of unnatural-cause mortality (adj. RR 0.09, 
95% CI 0.01–0.69). Our findings suggest that the mortal-
ity gap in people with psychotic disorders remains huge and 
may be wider for unnatural-cause mortality than previously 
reported. Efforts should now focus on further understanding 
and targeting these tractable clinical and social risk factors 
of excess mortality. Early intervention and dual diagnosis 
services may play a key role in achieving more rapid remis-
sion and carer involvement and addressing substance use 
problems to reduce excess mortality in psychosis.
Key words:  schizophrenia/mortality/psychosis/ 
risk factors
Introduction
People with schizophrenia and other psychotic disorders 
die earlier than their peers in the general population, with 
recent estimates suggesting by around 15–20  years.1–10 
Although life expectancy in the general population has 
risen over recent decades in developed countries,11 it is 
unclear whether the mortality gap for people with psy-
chotic disorder has widened or narrowed.4,5,9,12–16 Evidence 
as to whether excess mortality is predominantly due to 
unnatural or natural causes of death remains equivo-
cal.2,7,9,12 In addition, mortality has rarely been investi-
gated in unselected cohorts of first-episode cases of all 
psychotic disorders. Further, most studies conducted 
to date have compared mortality in psychosis with that 
in the national rather than local population,9 thereby 
ignoring geographical variation in mortality rates.17,18 
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A number of factors have been proposed to account for 
the mortality gap such as smoking, alcohol use, obesity, 
and other unhealthy lifestyle factors that increase risk 
of a broad range of physical conditions, limited access 
to healthcare, poorer quality of healthcare received, or 
adverse side effects of second-generation antipsychotic 
medication.9,16,19–24 Conflicting results have been recently 
reported as to whether illicit drug use contributes to 
excess mortality in psychosis.2,25,26 Overall, evidence on 
modifiable clinical and social risk factors which may 
predict premature death in this population remains very 
limited.
We aimed to: (1) investigate mortality in a cohort of 557 
individuals with first-episode psychosis, who initially pre-
sented to mental health services within defined catchment 
areas of the Aetiology and Ethnicity in Schizophrenia and 
Other Psychoses (ӔSOP) study and subsequently traced 
over an approximately 10-year period in the ӔSOP-10 
study; (2) compare mortality in this cohort with that in 
the local general population; and (3) investigate baseline 
clinical and social factors associated with an increased 
risk of premature death.
Methods
Sample
This study forms part of ӔSOP-10, a 10-year follow-
up study of a cohort of 557 individuals with a first epi-
sode of psychosis initially identified in the 2 centers (ie, 
Southeast London, Nottinghamshire, United Kingdom) 
of the ӔSOP study.27 All patients with a first episode 
of psychosis who presented to mental health services 
within defined catchment areas in Southeast London and 
Nottinghamshire were screened for inclusion at base-
line. This yielded a sample of n = 532 incident cases. We 
included 25 additional cases in ӔSOP-10 identified as 
part of the MRI data collection at baseline. The study 
received full ethical approval from the relevant local 
research ethics committees. Full details of the methods 
of ӔSOP-10 have been reported by Morgan et al.28
Case-Tracing Procedure
We identified all occurrences of death and emigration 
in the cohort over a combined total of 5183.9 years of 
follow-up until December 12, 2012 (mean length of fol-
low-up 10.0 years, SD = 2.3) via a person-tracing proce-
dure conducted on our behalf  by the Office for National 
Statistics (ONS) for England and Wales and the General 
Register Office (GRO) for Scotland using name, sex, date 
of birth, and last known address. For all identified deaths, 
principal underlying causes of death were determined 
according to the International Classification of Diseases, 
10th revision (ICD-10),29 as recorded on copies of death 
certificates obtained from ONS. We grouped these into 
3 broad categories (using ICD-10 codes): natural causes 
to refer to the disease which initiated the train of events 
directly leading to death29 (A00–Q99), unnatural (or 
external) causes to refer to the circumstances of the acci-
dent or violence which produced the fatal injury29 (U50.9, 
V01–Y89), and unknown causes to refer to symptoms, 
signs, and abnormal clinical and laboratory findings, not 
elsewhere classified29 (R00–R99). Unnatural causes of 
death included accidents (V01–X59) and suicide (X60–
X84 and Y10–Y34). Consistent with the classification 
of causes of death by ONS, both intentional self-harm 
(X60–X84) and events of undetermined intent (Y10–
Y34) were coded as suicide. The underlying cause of 
death recorded on copies of death certificates was further 
ascertained based on extensive information collated from 
clinical records at follow-up using an extended version of 
the World Health Organization (WHO) Life Chart.28,30
Data Collection
Detailed information on sociodemographic characteris-
tics (including sex, age, and ethnicity), clinical presenta-
tion (including diagnosis, duration of untreated psychosis 
(DUP), and illicit drug use in past year), and social fac-
tors (including education, employment, involvement of 
family at first contact with mental health services) was 
collected at baseline.31 In the extended version of the 
WHO Life Chart,28,30 data on time to first remission 
were collected at follow-up. Remission was defined as an 
absence of clinical psychotic symptoms for a period of at 
least 6 months.28,32 Data on all-, natural-, and unnatural-
cause mortality rates (in the population at risk) and pop-
ulation estimates, stratified by sex, age band, year, and 
the Census Area Statistics (CAS) wards in Lambeth and 
Southwark in Southeast London (33 CAS wards) and 
Nottinghamshire (95 CAS wards), in which cases were 
initially identified, were obtained from ONS for the dura-
tion of the follow-up period.
Data Analysis
We calculated crude mortality rates for all causes, nat-
ural causes, unnatural causes, and unknown causes of 
death per 100  000 person-years by baseline sociode-
mographic characteristics for people with first-episode 
psychosis. We constructed Kaplan–Meier plots and 
used Cox regression to inspect variation in risk of  death 
over time according to sociodemographic, clinical, and 
social characteristics. Date of  first presentation to ser-
vices was used as the entry point and date of  death, last 
contact, date of  emigration, or the end of  follow-up as 
the end point, whichever came sooner. Log-rank tests 
were used to examine whether probability of  death over 
time varied by sociodemographic, clinical, and social 
characteristics. Poisson regression modeling was con-
ducted to quantify the effect of  these characteristics on 
risk of  all-, natural-, and unnatural-cause mortality in 
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people with first-episode psychosis while controlling for 
potential confounders based on (a) the level of  change 
in the magnitude of  effect of  interest and (b) whether 
potential confounders were associated with the outcome 
(by examining whether adding variables to the model 
improved model fit [P <.05] using likelihood ratio tests 
[LRTs] to minimize problems of  overfitted models with 
unstable parameter estimates). Finally, we employed 
indirect standardization to compare mortality risk in 
people with first-episode psychosis with the risk in the 
local general population. Standardized mortality ratios 
(SMRs) and 95% confidence intervals (CIs) for all, 
natural, and unnatural causes of  death were calculated 
based on the observed number of  deaths in the cohort 
and the expected number of  deaths for each study center 
by age band and sex derived from ONS all-, natural-, 
and unnatural-cause mortality rates (in the population 
at risk) and population estimates. All analyses were con-
ducted using Stata version 12.33
Results
Mortality in the Cohort
Of the 557 cases with first-episode psychosis identified at 
baseline, 8 were excluded based on additional diagnos-
tic information not available at baseline. Of the remain-
ing 549 cases, 39 (7.1% of the sample, 717.3 per 100 000 
person-years) cases had died, 15 (2.7%, 275.9 per 100 000 
person-years) due to natural causes, 21 (3.8%, 386.3 per 
100  000 person-years) due to unnatural causes, and 3 
(0.6%, 55.2 per 100 000 person-years) due to unknown 
causes of death. Cases with natural causes of death pre-
dominantly died from diseases of the digestive system 
(n = 7, 1.3%, 128.8 per 100  000 person-years), with 3 
(0.6%, 55.2 per 100  000 person-years) of these having 
died from definite alcohol-related causes (K70.9 alcoholic 
liver disease, n = 1; K74.6 other and unspecified cirrhosis 
of liver, n = 1; K86.0 alcohol-induced chronic pancreati-
tis, n = 1) and 3 (0.6%, 55.2 per 100 000 person-years) 
from probable alcohol-related causes (K25.4 chronic or 
unspecified gastric ulcer with hemorrhage, n = 1; K26.5 
chronic or unspecified duodenal ulcer with perforation, n 
= 1; K76.0 Fatty liver, n = 1) (see supplementary table 1). 
The most common unnatural cause of death was suicide 
(n = 13, 2.4%, 239.1 per 100 000 person-years) (see sup-
plementary table 1). Of the 17 cases with unnatural-cause 
death for whom we had reliable information on baseline 
illicit drug use (81.0% of 21 who had died from unnatural 
causes), 12 (70.6% of 17) had reported at baseline hav-
ing used illicit drugs in the previous year (cannabis use, 
n = 7 [41.1%]; amphetamine use, n = 1 [5.9%]; multiple 
substance use, n = 4 [23.5%]). At follow-up, 3 cases (0.6%, 
55.2 per 100  000 person-years) had died from acciden-
tal poisoning (heroin intoxication, n = 2 [0.4%, 36.8 per 
100 000 person-years]; olanzapine and valproate intoxica-
tion, n = 1 [0.2%, 18.4 per 100 000 person-years]).
Mortality rates by sociodemographic characteristics for 
all causes, natural causes, and unnatural causes of death 
are shown in table 1. Mortality rates for all causes, natu-
ral causes, and unnatural causes of death were similar in 
London and Nottingham. All-cause and unnatural-cause 
mortality rates were lower in women (487.0 per 100 000 
person-years) than in men (881.0 per 100  000 person-
years), with Kaplan–Meier survival curves and findings 
from Cox regression suggesting that women experienced 
a lower risk of unnatural-cause mortality over time 
than men (see supplementary table  2, supplementary 
figure  1). Younger cases had lower mortality rates for 
all causes (466.3 per 100 000 person-years) and natural 
causes (265.6 per 100  000 person-years). This was also 
reflected in a shorter time to all- and natural-cause death 
for older cases (see supplementary table 2, supplementary 
figure  2). Mortality rates for all causes, natural causes, 
and unnatural causes of death were slightly lower in cases 
from a Black and Minority Ethnic (BME) group than in 
white British cases, but CIs for these point estimates were 
wide. While there was some limited variation in mortality 
rates by time since first presentation to services, overall, 
these were broadly similar over the follow-up period (see 
supplementary table 3).
Poisson regression modeling revealed a decreased risk 
of unnatural-cause mortality in women compared with 
men after controlling for age at baseline (see table  2). 
The sex-adjusted rate ratio for the effect of age at base-
line indicated significantly reduced risk of all-cause and 
natural-cause mortality in younger cases. There were no 
statistically significant differences in risk of mortality by 
broad ethnic group.
Mortality in the ӔSOP Cohort Compared With the 
Local General Population
SMRs for all, natural, and unnatural causes of death are 
shown in table 3. There was an almost 4-fold increase in 
all-cause mortality in the cohort compared with that in 
the general population (SMR 3.6, 95% CI 2.6–4.9). All-
cause SMRs were of similar magnitude in the 2 study sites 
(London and Nottingham), slightly more pronounced in 
men (SMR 4.1, 95% CI 2.8–5.9) than in women (SMR 
2.8, 95% CI 1.6–5.1), and lessened for cases in higher 
age bands. When broken down by natural and unnatu-
ral causes of death, the increase in natural-cause mortal-
ity was approximately 2-fold, compared with a 13-fold 
increase in unnatural-cause mortality. Natural-cause 
SMRs were equally elevated in London and Nottingham 
as well as in men and women, but not statistically signifi-
cant at conventional levels (ie, P < .05). There was some 
weak evidence that the increase in natural-cause mortal-
ity was higher in age bands 30–44 years and 45–59 years 
than in age bands 16–29 years and 60–74 years; however, 
CIs were wide and overlapped across age bands. There 
was no strong evidence that unnatural-cause SMRs 
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varied by place, sex, or age and these SMRs remained 
high for older cases (ie, aged 60–74 years). When we fur-
ther examined risk of suicide as the most common unnat-
ural cause of death in the cohort, this was 20-fold raised 
compared with that in the local general population (SMR 
20.0, 95% CI 11.7–34.5). Although we found no evidence 
that SMRs for suicide varied by sex and age, there was 
some evidence that the increase in risk of suicide was 
more marked in London (SMR 28.3, 95% CI 15.7–51.1) 
than in Nottingham (SMR 7.7, 95% CI 1.9–30.8), though 
CIs were very wide and overlapped to a degree.
All-, Natural- and Unnatural-Cause Mortality by 
Clinical and Social Factors
There was evidence from Kaplan–Meier survival curves 
that a long DUP (see supplementary figure 3) and a long 
time to first remission (see supplementary figure 4) were 
associated with a shorter time to all- and natural-cause 
death. Findings from Cox regression further indicated 
that the association between time to first remission and 
natural-cause death over time held after controlling for 
age at baseline and sex (see supplementary table  4). In 
addition, illicit drug use in the year prior to baseline was 
associated with a shorter time to all- and unnatural-cause 
death, while controlling for age and sex (see supplemen-
tary table 4, supplementary figure 5). There was also evi-
dence of a longer time to unnatural death for cases with 
full family involvement at first contact with services (see 
supplementary table 4, supplementary figure 6).
Rate ratios for all-, natural- and unnatural-cause mor-
tality by clinical and social factors are shown in table 4. 
While a long DUP was associated with an increased risk 
of all- and natural-cause mortality in unadjusted analy-
ses, this association was attenuated and ceased to be sta-
tistically significant when adjusting for age at baseline 
and sex. Similarly, after controlling for these variables, 
the association between a long time to first remission and 
increased risk of all-cause mortality was reduced and no 
longer significant. However, the rate ratio for a long time 
to first remission and increased risk of natural-cause mor-
tality held after controlling for age and sex (see table 4) as 
well as DUP (LRT, χ2 = 0.01, P = .92). Further, illicit 
drug use was associated with a 2- to 3-fold increased risk 
of all- and unnatural-cause mortality while controlling 
for age and sex. There was no evidence of confounding of 
the association between drug use and all-cause mortality 
by DUP (LRT, χ2 = 4.48, P = .11), time to first remis-
sion (LRT, χ2 = 2.31, P = .13), and family involvement 
at first contact (LRT, χ2 = 5.27, P = .15). However, we 
found some evidence that the association between illicit 
drug use and unnatural-cause mortality was confounded 
by lack of family involvement at first contact (LRT, 
χ2 = 7.22, P = .03). Although this association was attenu-
ated, there was still some evidence of an approximately 
3-fold increased risk of unnatural-cause mortality in 
cases using illicit drugs (adj. rate ratio [RR] 3.25, 95% CI 
0.96–11.03, P = .06). Finally, a significantly reduced risk 
of unnatural-cause mortality was found in cases with full 
family involvement compared with those with no family 
involvement at first contact with services, while control-
ling for age and sex. This association held when we fur-
ther adjusted for illicit drug use (χ2 = 2.65, P = .10).
Discussion
Main Findings
This study investigated all-, natural-, and unnatural-cause 
mortality in a large, epidemiologically characterized 
cohort of 557 individuals with first-episode psychosis at 
10 years follow-up. More cases had died from unnatural 
Table 3. Standardized Mortality Ratios (SMRs) for All Causes, Natural Causes, and Unnatural Causes of Deatha
All Causes Natural Causes Unnatural Causes
Observed 
Deaths
Expected 
Deaths SMR 95% CI
Observed 
Deaths
Expected 
Deaths SMR 95% CI
Observed 
Deaths
Expected 
Deaths SMR 95% CI
Total 39 10.8 3.6 2.6–4.9 15 9.1 1.7 1.0–2.7 21 1.6 13.3 8.7–20.4
Study center
 London 23 6.7 3.5 2.3–5.2 9 5.6 1.6 0.8–3.1 13 0.9 14.0 8.2–24.2
 Nottingham 16 4.2 3.8 2.3–6.2 6 3.5 1.7 0.8–3.8 8 0.7 12.2 6.1–24.4
Sex
 Women 11 3.9 2.8 1.6–5.1 6 3.6 1.7 0.7–3.7 4 0.3 14.5 5.4–38.7
 Men 28 6.9 4.1 2.8–5.9 9 5.5 1.6 0.9–3.2 17 1.3 13.0 8.1–20.9
Age band
 16–29 years 7 1.0 7.4 3.5–15.5 0 0.4 0 — 7 0.5 13.2 6.3–27.8
 30–44 years 18 3.1 5.8 3.7–9.2 5 2.3 2.2 0.9–5.3 11 0.8 14.4 8.0–26.1
 45–59 years 8 3.3 2.5 1.2–4.9 6 3.0 2.0 0.9–4.5 2 0.2 9.1 2.3–36.6
 60–74 years 6 3.5 1.7 0.8–3.8 4 3.5 1.2 0.4–3.1 1 0.1 13.6 1.9–96.8
Note: aIndirectly standardized to the age band, sex, and center-specific stratum rates for the population at-risk in Southeast London and 
Nottinghamshire; SMRs > 1 indicate the magnitude of excess mortality in people with first-episode psychosis.
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than natural causes, with suicide being the leading cause of 
death. All- and unnatural-cause mortality rates remained 
broadly similar across the follow-up period. Further, a sig-
nificantly reduced risk of unnatural-cause mortality was 
observed in women compared with men. All-cause mortal-
ity in the cohort was raised almost 4-fold. When broken 
down further, an approximately 2-fold increase in natural-
cause mortality was observed, compared with a 13-fold 
increase in unnatural-cause mortality and a 20-fold increase 
in risk of suicide. The longer the time to first remission, the 
higher the risk of natural-cause mortality; illicit drug use 
increased all-cause and (at least partially explained by lack 
of family involvement at first contact) unnatural-cause 
mortality risk; and full family involvement at first contact 
reduced risk of unnatural-cause mortality.
Methodological Considerations
We investigated the association between baseline clinical 
and social factors and mortality risk over an approxi-
mately 10-year period. However, clinical and social fac-
tors may have varied over time. For example, we observed 
no difference in mortality rates by employment status 
as assessed at baseline and, even though a large propor-
tion of cases was unemployed at both baseline and fol-
low-up,28 this may have varied at the level of individual 
cases and therefore attenuated differences in mortality 
rates.34 However, restricting our analyses to baseline fac-
tors allowed us to establish temporal priority of these 
overmortality outcome. Further, mortality as an outcome, 
though markedly elevated compared with the local gen-
eral population, was, from a purely statistical viewpoint, 
rare in this cohort, such that CIs were wide, introducing 
imprecision in point estimates of rate ratios and SMRs. 
Further follow-up of this cohort would allow us to limit 
the scope for Type 1 error and ascertain findings from the 
current set of analyses at 10-year follow-up. In addition, 
we cannot rule out the possibility of unmeasured con-
founding by other important factors such as smoking, 
obesity and other unhealthy lifestyle factors, medication, 
and access to, or quality of, healthcare.9,16,19–24 One of the 
most important unmeasured factors in the context of this 
study was alcohol use at baseline. Although this would 
have allowed us, as for baseline illicit drug use, to inves-
tigate its role as a risk factor for all-, natural- and unnat-
ural-cause mortality, we were able to examine alcohol 
use as a principal underlying cause of  death through the 
person-tracing procedure by ONS and GRO. Consistent 
with earlier research2–6,8–10,12,35–40 and the classification of 
principal underlying causes of death by ONS according 
to ICD-10,29 alcohol-related diseases (as the disease which 
initiated the train of events directly leading to death) were 
grouped as natural causes, whereas accidental poisoning 
was classified as unnatural causes of death to enhance 
comparability of our findings. In interpreting these, it 
is important to recognize that mortality is likely to be 
multi-factorial and alcohol and illicit drug use may con-
tribute both as a risk factor several years prior to death, 
and as a principal underlying cause directly leading to 
death. However, although our findings are in support of 
such a role for illicit drug use as both risk factor and prin-
cipal underlying cause, as well as for alcohol use as a prin-
cipal underlying cause, no firm conclusions can be drawn 
about alcohol use as a risk factor for morality. A notable 
strength of this study is that it was based on a large, epi-
demiologically characterized cohort of unselected first-
episode cases presenting to mental health services within 
defined catchment areas, for which attrition bias has been 
reported to be minimal for the 10-year follow-up period.28 
Given many earlier studies have not been cohorts com-
prising first-episode cases but included patients with 
more severe and enduring psychosis, our findings may 
not be directly comparable with those reported in the 
wider literature. We were further able to compare mortal-
ity in this cohort with that in the local general popula-
tion of the defined catchment areas, thereby addressing 
the issue that mortality rates in the general population 
vary (markedly) by place,17,18 which may have obscured 
earlier reported SMRs quantifying the excess mortality 
in psychotic disorders.
Comparison With Previous Research
Over the past decades, consistent evidence has accrued 
that people with psychotic disorder have higher mortal-
ity rates than the general population.1–9 Our findings add 
to this by demonstrating an almost 4-fold increase in all-
cause mortality in the ӔSOP cohort compared with the 
general population. Even though we could not directly 
compare results between decades, in line with evidence 
from earlier studies, we noted period effects suggestive 
of a widening mortality gap, insofar as a greater relative 
all-cause mortality risk was observed for the decade of 
follow-up for this cohort than that reported for earlier de- 
cades.4,9,12,35,36 Although the 2-fold increase in natu-
ral-cause mortality echoed that of earlier reports, we 
observed a staggering 13-fold increase in unnatural-cause 
mortality and a 20-fold increase in risk of suicide, with 
some evidence of there being a more marked excess of 
suicide in London than in Nottingham. The SMRs for 
unnatural-cause mortality (and suicide) that we found in 
the ӔSOP cohort are markedly higher than the median 
SMRs of 7.5 for unnatural causes (and 12.9 for suicide) 
reported in the systematic review by Saha et al,9 including 
3 (10) studies, all conducted in earlier decades.
Although several explanations have been put forward 
to account for this mortality gap,9,16,19–24 only a few studies 
have investigated the clinical and social factors that may 
increase risk of premature death in psychosis. We found 
evidence that a long time to first remission may increase risk 
of natural-cause mortality in our sample. Although careful 
replication is required, with account taken of unmeasured 
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confounders and other potentially important explanatory 
factors, such as suboptimal treatment of physical health 
problems, engagement with services, and medication use 
in the time prior to death before firm conclusions can be 
drawn, it is intriguing to speculate that this finding may 
point to shared genetic and environmental risk factors 
indicating severe and enduring psychosis and comorbid 
somatic conditions.23,41–43 Hepgul et al44 recently reported 
increased C-reactive protein levels, as a marker of increased 
inflammation, and higher body mass index in first-episode 
psychosis patients exposed to childhood adversity. Given 
there is also evidence that childhood adversity is associated 
with an increased risk of developing psychosis,45 it may 
be speculated that elevated inflammation may increase 
susceptibility to both (enduring) psychotic disorder and 
metabolic abnormalities, which, in turn, may increase risk 
of natural-cause mortality. Alternatively, a longer time to 
remission is likely to involve prolonged periods (and higher 
dose) of exposure to antipsychotic medication, which have 
been posited to increase natural-cause mortality via meta-
bolic mechanisms.46–48 However, overall, findings on the 
association between exposure to antipsychotic medica-
tion and natural-cause mortality remain inconsistent.2,48,49 
What is more, when interpreting findings on natural-cause 
mortality in the ӔSOP cohort, it also needs to be taken 
into account that at least one-fifth of natural-cause deaths 
were alcohol-related. In contrast to Neeleman’s37 meta-
analysis, but echoing more recent studies,38,39 we found no 
difference in all-, natural-, and unnatural-cause mortality 
between nonaffective and affective psychoses. Consistent 
with earlier reports,25,26 however, at variance with recent 
findings by Crump et al,2 our findings suggest that illicit 
drug use is associated with a 2- to 3-fold increased risk of 
all- and unnatural-cause mortality. Although 2 cases had 
died from heroin intoxication and, therefore, some of the 
elevated risk of unnatural-cause mortality was due to acci-
dental poisoning by this drug, a considerable proportion 
of cases who had died from unnatural causes at follow-
up had reported having used cannabis only at baseline. 
Notwithstanding that some of the latter may have gone on 
to use other illicit drugs, this raises the question of alterna-
tive explanations for this finding. Indeed, we found some 
evidence that a lack of family involvement at first con-
tact with services confounded to a degree the association 
between illicit drug use and unnatural-cause mortality. 
Although lack of family involvement may have served as 
a crude proxy of family fragmentation, it remains difficult 
to disentangle whether it is family fragmentation that may 
have exacerbated illicit drug use and, in turn, increased 
risk of unnatural-cause mortality, or vice versa, illicit drug 
use rendered families more fragmented and, thereby, indi-
viduals more vulnerable to death from unnatural causes. 
It does suggest, however, that these factors may need to be 
targeted more effectively by mental health services.
It has been repeatedly noted as part of suicide preven-
tion strategies in early psychosis that family members 
and carers should be closely involved in risk management 
plans.50,51 However, to date, there has been only limited 
evidence to support this claim. Our finding that family 
involvement at first contact reduces risk of unnatural-
cause mortality, although requiring replication, is, to our 
knowledge, the first to base family and carer involvement 
in such prevention strategies on firmer empirical ground. 
Given, however, that, in line with earlier research,40 
unnatural-cause mortality rates remained high across the 
follow-up period, and assuming family involvement may 
be relevant in reducing unnatural-cause mortality beyond 
first contact, this may need to be extended to facilitate 
carer involvement throughout all stages of the illness.40
The reduced risk of unnatural-cause mortality that we 
observed in women compared with men is consistent with 
most earlier studies investigating this issue to date.40,52 
Wahlbeck et al10 noted that variation in unnatural-cause 
mortality by sex may result from differences in help-seek-
ing behavior, given women may be more likely than men 
to talk to health professionals about their mental health. 
It is also noteworthy that all-cause SMRs lessened with 
increasing age of cases in our sample, as it suggests that 
the burden of excess mortality occurs at younger ages and 
confirms the fact that people with psychosis die younger 
than the general population. Although mortality risk was 
slightly lower in cases from the BME compared with the 
white British group, in contrast to earlier research,23,24 we 
found no difference beyond what would be expected by 
chance. Consistent with Dickerson et  al,23 the absence 
of systematic differences across ethnic groups or, as has 
been reported earlier, an even lower mortality risk in BME 
groups,23,24 may be accounted for by social and health dis-
parities in BME populations being offset through the, rel-
atively speaking, greater attention to medical treatment of 
physical health problems in patients in the care of mental 
health services.
Conclusions
Our findings suggest that the mortality gap in people with 
schizophrenia and other psychoses remains high and may 
be wider for unnatural-cause mortality than reported in 
earlier studies; people with psychosis still do not appear to 
be benefitting from improvements in healthcare available 
to the general population.9,34 Efforts should now focus on 
further understanding and targeting these tractable clini-
cal and social risk factors of excess mortality. Early inter-
vention and dual diagnosis services may play a key role in 
achieving more rapid remission and carer involvement and 
addressing substance use problems to reduce excess mor-
tality in psychosis. Only then, we expect a narrowing in the 
mortality gap of psychosis in forthcoming decades.
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